Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 2
1970 1
1971 3
1972 3
1973 1
1975 1
1976 1
1977 1
1978 1
1979 1
1980 4
1981 2
1982 3
1983 5
1984 7
1985 5
1986 8
1987 8
1988 11
1989 6
1990 14
1991 16
1992 7
1993 16
1994 24
1995 41
1996 35
1997 38
1998 35
1999 49
2000 54
2001 43
2002 47
2003 49
2004 61
2005 62
2006 64
2007 46
2008 55
2009 51
2010 39
2011 41
2012 39
2013 43
2014 43
2015 44
2016 41
2017 35
2018 33
2019 26
2020 22
2021 24
2022 18
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

1,215 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of biochemical changes and treatment efficacy in patients with bruxism following botulinum toxin or splint therapy: a randomized clinical trial.
Karagozoglu I, Ozcan M. Karagozoglu I, et al. Clin Oral Investig. 2023 Dec 28;28(1):43. doi: 10.1007/s00784-023-05453-w. Clin Oral Investig. 2023. PMID: 38153567 Clinical Trial.
OBJECTIVES: This clinical study aims to analyze the levels of cortisol, dehydroepiandrosterone (DHEA), and tumor necrosis factor alpha (TNF-alpha) in the gingival crevicular fluid (GCF) of persons with bruxism and to compare the efficacy of botulinum toxin (botox) and occl …
OBJECTIVES: This clinical study aims to analyze the levels of cortisol, dehydroepiandrosterone (DHEA), and tumor necrosis factor alph …
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE. Petri MA, et al. Arthritis Rheum. 2004 Sep;50(9):2858-68. doi: 10.1002/art.20427. Arthritis Rheum. 2004. PMID: 15452837 Free article. Clinical Trial.
OBJECTIVE: To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SLE) disease activity and its symptoms. ...Acne and hirsutism were reported in 33% and 16%, respectively, of the prasterone group and i …
OBJECTIVE: To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SL …
Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M. Labrie F, et al. Menopause. 2017 Nov;24(11):1246-1256. doi: 10.1097/GME.0000000000000910. Menopause. 2017. PMID: 28640161 Clinical Trial.
OBJECTIVE: To analyze the effects of intravaginal prasterone obtained in the three randomized clinical studies performed in postmenopausal women suffering from moderate to severe (MS) dyspareunia due to vulvovaginal atrophy (VVA). ...RESULTS: In 436 women treated with 0.50 …
OBJECTIVE: To analyze the effects of intravaginal prasterone obtained in the three randomized clinical studies performed in postmenop …
Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Labrie F, et al. Menopause. 2009 Sep-Oct;16(5):907-22. doi: 10.1097/gme.0b013e31819e8e2d. Menopause. 2009. PMID: 19436225 Clinical Trial.
OBJECTIVE: Because the secretion of dehydroepiandrosterone (DHEA), the exclusive source of sex steroids in postmenopausal women, is already decreased by 60% and continues to decline at the time of menopause, the objective of this study was to examine the effect of intravag …
OBJECTIVE: Because the secretion of dehydroepiandrosterone (DHEA), the exclusive source of sex steroids in postmenopausal women, is a …
Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia.
Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Labrie F, et al. Climacteric. 2011 Apr;14(2):282-8. doi: 10.3109/13697137.2010.535226. Epub 2011 Jan 18. Climacteric. 2011. PMID: 21244215 Clinical Trial.
OBJECTIVE: To examine the effect of intravaginal dehydroepiandrosterone (DHEA) on pain at sexual activity (dyspareunia) identified as the most bothersome symptom of vaginal atrophy in postmenopausal women at both screening and day 1. METHODS: This prospective, randomized, …
OBJECTIVE: To examine the effect of intravaginal dehydroepiandrosterone (DHEA) on pain at sexual activity (dyspareunia) identified as …
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Sánchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, Sherrer YR, McIlwain HH, Freeman PG, Aranow C, Petri MA, Deodhar AA, Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsey-Goldman R, McKay JD, Kivitz AJ, Mease PJ, Winkler AE, Kahl LE, Lee AH, Furie RA, Strand CV, Lou L, Ahmed M, Quarles B, Schwartz KE. Sánchez-Guerrero J, et al. J Rheumatol. 2008 Aug;35(8):1567-75. Epub 2008 Jul 15. J Rheumatol. 2008. PMID: 18634158 Clinical Trial.
METHODS: 155 patients with SLE received 200 mg/day prasterone or placebo for 6 months in a double-blind phase. Subsequently, 114 patients were re-randomized to receive 200 or 100 mg/day prasterone for 12 months in an open-label phase. ...There was no overall change …
METHODS: 155 patients with SLE received 200 mg/day prasterone or placebo for 6 months in a double-blind phase. Subsequently, 114 pati …
Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women.
Meno-Tetang GM, Blum RA, Schwartz KE, Jusko WJ. Meno-Tetang GM, et al. J Clin Pharmacol. 2001 Nov;41(11):1195-205. doi: 10.1177/00912700122012742. J Clin Pharmacol. 2001. PMID: 11697752 Clinical Trial.
This study sought to determine effects of multiple dosing of prasterone (DHEA, dehydroepiandrosterone) on the pharmacokinetics of prednisolone and endogenous cortisol secretion. ...Fourteen normal women (ages 30.1 +/- 5.4 years) received single-dose oral prednisone …
This study sought to determine effects of multiple dosing of prasterone (DHEA, dehydroepiandrosterone) on the pharmacokinetics …
Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Labrie F, et al. Menopause. 2009 Sep-Oct;16(5):923-31. doi: 10.1097/gme.0b013e31819e85c6. Menopause. 2009. PMID: 19424093 Clinical Trial.
METHODS: This prospective, randomized, double-blind, and placebo-controlled phase III clinical trial has evaluated the effect of daily local intravaginal application of Prasterone (dehydroepiandrosterone; DHEA) for 12 weeks on the domains of sexual dysfunction, name …
METHODS: This prospective, randomized, double-blind, and placebo-controlled phase III clinical trial has evaluated the effect of daily local …
The effect of pilates training on hormonal and psychophysical function in older women.
Farzane A, Koushkie Jahromi M. Farzane A, et al. J Sports Med Phys Fitness. 2022 Jan;62(1):110-121. doi: 10.23736/S0022-4707.21.12089-4. Epub 2021 Feb 8. J Sports Med Phys Fitness. 2022. PMID: 33555671 Clinical Trial.
The present study aimed to determine the effect of eight weeks of pilates training on diurnal salivary cortisol, dehydroepiandrosterone sulfate (DHEA-S), and cortisol to DHEA-S ratio, cardiorespiratory fitness (CF), and psychological function in older women. ...
The present study aimed to determine the effect of eight weeks of pilates training on diurnal salivary cortisol, dehydroepiandrosterone
Effects of resistance training on bone mineral density and resting serum hormones in female collegiate distance runners: a randomized controlled pilot trial.
Kobayashi T, Seki S, Hwang I. Kobayashi T, et al. J Sports Med Phys Fitness. 2023 Jun;63(6):765-772. doi: 10.23736/S0022-4707.23.14571-3. Epub 2023 Mar 8. J Sports Med Phys Fitness. 2023. PMID: 36884123 Free article. Clinical Trial.
We aimed to investigate changes in BMD and resting serum hormones, including dehydroepiandrosterone sulfate (DHEA-S) and estradiol (E2), before and after resistance training (RT) interventions in female collegiate distance runners. ...
We aimed to investigate changes in BMD and resting serum hormones, including dehydroepiandrosterone sulfate (DHEA-S) and estradiol (E …
1,215 results